PresseBox
Press release BoxID: 122968 (Profos AG)
  • Profos AG
  • Josef-Engert-Str. 11
  • 93053 Regensburg
  • http://www.profos.de
  • Contact person
  • Stephanie Steck
  • +49 (941) 94262-0

Profos introduces EndoGrade™ Ovalbumin

Today Profos AG announced the launch of EndoGrade™ Ovalbumin with highest quality (endotoxin conc. < 1 EU/mg) for in vivo and in vitro immunological studies

(PresseBox) (Regensburg, ) Microbiological contamination is a well recognized problem of research reagents in many applications. Especially elevated endotoxin levels often lead to misinterpretations in cell culture or animal model experiments. Today, Profos AG, Regensburg is pleased to announce the imminent launch of EndoGrade™ Ovalbumin.
With the first of the globally unique EndoGrade™ products – with lowest endotoxin content – Profos sets new quality guidelines for reagents in immunology and cell culture.

The glycoprotein ovalbumin is the main constituent in egg white. Currently ovalbumin is one of the extensively used proteins in animal studies and also an established model allergen for airway hyper-responsiveness (AHR). Using its proprietary technology EndoTrap® Profos AG established an efficient endotoxin removal process to provide ovalbumin with lowest endotoxin content. The product is designed to give researchers the ability to ensure accurate results by avoiding side effects by endotoxin stimulation.

With EndoGrade™ Ovalbumin Profos takes another step to become a global market leader in the field of endotoxin removal systems and high-quality endotoxin-free products. Further products are in development and will expand the growing portfolio continuously.

Profos AG

Profos AG, founded in 2000, employs a total of 58 permanents staff and is certified according to ISO 9001:2000 and ISO13485:2003. Profos’ core competency is to exploit the principles of bacteriophage biology for pharmaceutical, diagnostic and research applications.